Latest and Breaking Cancer News

Study published in Neuro-Oncology shows brain tumor eradication and prolonged survival
3 February 2012, 5:00 am
(Canale Communications) Tocagen Inc. today announced the publication of data showing the company's investigational treatment for high grade glioma eradicates brain tumors and provides a dramatic survival benefit in mouse models of glioblastoma. Almost all mice receiving the top dose of Toca 511 followed by 5-FC were still alive at 180 days, which was the termination date for the experiment, whereas all control mice died by day 43. The article was published today in the February issue of the Neuro-Oncology journal.

UC San Diego Moores Cancer Center offers new hope for deadly brain tumor
3 February 2012, 5:00 am
(University of California - San Diego) In the United States, each year, approximately 10,000 patients are affected by recurrant glioblastoma multiforme. Now, a novel investigational device - available only at clinical trial sites - is offering new hope to these patients.

Regular use of vitamin and mineral supplements could reduce the risk of colon cancer
3 February 2012, 5:00 am
(Canadian Science Publishing (NRC Research Press)) Could the use of vitamin and mineral supplements in a regular diet help to reduce the risk of colon cancer and protect against carcinogens? A study published in the Canadian Journal of Physiology and Pharmacology found that rats given regular multivitamin and mineral supplements showed a significantly lower risk of developing colon cancer when they were exposed to carcinogens.

Conference focuses on vaccines for chronic diseases
3 February 2012, 5:00 am
(University of Texas Medical Branch at Galveston) At a symposium sponsored by the University of Texas Medical Branch at Galveston and scheduled for Feb. 7-9, an international group of researchers will discuss development of vaccines for addiction, cancer, chronic infectious diseases and neurodegenerative diseases.

Soy isoflavone supplements did not provide breast cancer protections
3 February 2012, 5:00 am
(American Association for Cancer Research) Findings suggest the effects of food may be more complex. Adverse effect observed in younger women.

New technology to tackle treatment-resistant cancers
3 February 2012, 5:00 am
(Institute of Physics) Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.

World Cancer Day points to prevention
3 February 2012, 5:00 am
(Dana-Farber Cancer Institute) Health care organizations from around the globe will come together on Saturday, Feb. 4 to promote cancer prevention as part of this year’s World Cancer Day.

A new screening method for prostate cancer
2 February 2012, 5:00 am
(NYU Langone Medical Center / New York University School of Medicine) A new study by NYU Langone Medical Center and Northwestern University Feinberg School of Medicine shows novel PSA velocity risk count testing may provide a more effective way for physicians to screen men for clinically significant prostate cancer. The new study, published online by the British Journal of Urology International, shows the benefits of tracking a man's PSA levels over time to help doctors more accurately assess his risk of life-threatening prostate cancer.

Combination drug therapy urged to battle lung cancer
2 February 2012, 5:00 am
(The Translational Genomics Research Institute) Combination drug therapy may be needed to combat non-small cell lung cancer, according to a study by the Translational Genomics Research Institute and Van Andel Research Institute. The study, "STAT3 is Activated by JAK2 Independent of Key Oncogenic Driver Mutation in Non-Small Cell Lung Carcinoma," was published online today, Feb. 2, 2012, by the PLoS ONE.

Sanford-Burnham researchers find molecular switch that allows melanoma to resist therapy
2 February 2012, 5:00 am
(Sanford-Burnham Medical Research Institute) In a paper published Feb. 3 in Cell, researchers at Sanford-Burnham Medical Research Institute identified a molecular switch that controls the protein Activating Transcription Factor 2 (ATF2), which is associated with poor prognosis in melanoma. This switch is controlled by protein kinase Cε (PKCε), which disables ATF2's tumor-suppressing activities, sensitizing cells to chemotherapy; Instead, ATF2's tumor-promoting activity is enhanced. The team also found that high levels of PKCε in melanoma are associated with poor prognosis.